Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

543 ARTÍCULOS , VIENDO DEL 1 AL 15

Massive Weight Loss From Rivastigmine Patch in an Older Patient: A Rare Case

Naharci MI, Veizi BGY, Katipoglu B, Akcan E, Yoruk F, Tasci I.

J Clin Psychopharmacol. 2022 Mar-Apr 01;42(2):222-224. doi: 10.1097/JCP.0000000000001254.

Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease

Iqubal A, Iqubal MK, Fazal SA, Pottoo FH, Haque SE.

Curr Mol Pharmacol. 2022;15(1):23-50. doi: 10.2174/1874467214666210309115605.

Roles of Cannabidiol in the Treatment and Prevention of Alzheimer's Disease by Multi-target Actions

Zhang XB, Li J, Gu J, Zeng YQ.

Mini Rev Med Chem. 2022;22(1):43-51. doi: 10.2174/1389557521666210331162857.

Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer's Disease

Kumar B, Thakur A, Dwivedi AR, Kumar R, Kumar V.

Curr Med Chem. 2022;29(10):1757-1803. doi: 10.2174/0929867328666210512005508.

Recommendations for Preclinical Testing of Treatments Against Alzheimer's Disease-Related Epileptiform Spikes in Transgenic Rodent Models

Jin N, Babiloni C, Drinkenburg WH, Hajós M, Nygaard HB, Tanila H.

J Alzheimers Dis. 2022;88(3):849-865. doi: 10.3233/JAD-210209.

An Overview of β-Amyloid Cleaving Enzyme 1 (BACE1) in Alzheimer's Disease Therapy: Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor

Ugbaja SC, Lawal MM, Kumalo HM.

Curr Med Chem. 2022;29(1):114-135. doi: 10.2174/0929867328666210608145357.

Direct Modulation of the Gut Microbiota as a Therapeutic Approach for Alzheimer's Disease

Wang Y, Dykes GA.

CNS Neurol Disord Drug Targets. 2022;21(1):14-25. doi: 10.2174/1871527320666210806165751.

Alzheimer's Disease and β-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design

Ugbaja SC, Lawal IA, Kumalo HM, Lawal MM.

Curr Drug Targets. 2022;23(3):266-285. doi: 10.2174/1389450122666210809100050.

PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in the Treatment of Alzheimer's Disease

Shahbaz SK, Koushki K, Sathyapalan T, Majeed M, Sahebkar A.

Curr Neuropharmacol. 2022;20(2):309-323. doi: 10.2174/1570159X19666210823103020.

Interleukin-17A in Alzheimer's Disease: Recent Advances and Controversies

Yan XZ, Lai L, Ao Q, Tian XH, Zhang YH.

Curr Neuropharmacol. 2022;20(2):372-383. doi: 10.2174/1570159X19666210823110004.

Immunotherapeutics for AD: A Work in Progress

Sharma A, Anand JS, Kumar Y.

CNS Neurol Disord Drug Targets. 2022;21(9):752-765. doi: 10.2174/1871527320666210903101522.

Targeted Delivery of Montelukast for the Treatment of Alzheimer's Disease

Datusalia AK, Singh G, Yadav N, Gaun S, Manik M, Singh RK.

CNS Neurol Disord Drug Targets. 2022;21(10):913-925. doi: 10.2174/1871527320666210902163756.

Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations

Bukhari SNA.

Curr Drug Deliv. 2022;19(1):17-31. doi: 10.2174/1567201818666210910162750.

Phytotherapeutics against Alzheimer's Disease: Mechanism, Molecular Targets and Challenges for Drug Development

Gayathri S, Raghu CH, Fayaz SM.

CNS Neurol Disord Drug Targets. 2022;21(5):409-426. doi: 10.2174/1871527320666210920120612.

Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease

Sivaraman B, Raji V, Velmurugan BA, Natarajan R.

CNS Neurol Disord Drug Targets. 2022;21(5):427-449. doi: 10.2174/1871527320666210928160159.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias